Table 1 Baseline patient and tumor characteristics.
All Patients (N = 80) | ctDNA-Negative (N = 54) | ctDNA-Positive (N = 26) | P | ||||
|---|---|---|---|---|---|---|---|
Median age (range) | 48 | 25–85 | 48 | 25–70 | 52 | 28–85 | 0.537 |
Menopausal status | 0.290 | ||||||
Pre | 38 | 48% | 28 | 52% | 10 | 38% | |
Post | 40 | 50% | 25 | 46% | 15 | 58% | |
Unknowna | 2 | 3% | 1 | 2% | 1 | 4% | |
Race | 0.082 | ||||||
White | 64 | 80% | 45 | 83% | 19 | 73% | |
Black | 11 | 14% | 8 | 15% | 3 | 12% | |
Other | 5 | 6% | 1 | 2% | 4 | 15% | |
Ethnicity | 0.098 | ||||||
Not Hispanic | 76 | 95% | 53 | 98% | 23 | 88% | |
Hispanic | 4 | 5% | 1 | 2% | 3 | 12% | |
Germline BRCA1/2 mutation | 0.743 | ||||||
No | 62 | 77% | 42 | 78% | 20 | 77% | |
Yes | 11 | 14% | 8 | 15% | 3 | 12% | |
Unknowna | 7 | 9% | 4 | 7% | 3 | 12% | |
T stage | 0.128 | ||||||
1 | 13 | 16% | 10 | 19% | 3 | 12% | |
2 | 44 | 55% | 33 | 59% | 12 | 46% | |
3 | 19 | 24% | 8 | 17% | 10 | 38% | |
4 | 4 | 5% | 3 | 6% | 1 | 4% | |
Nodal status | 0.079 | ||||||
Negative | 48 | 60% | 36 | 67% | 12 | 46% | |
Positive | 32 | 40% | 18 | 33% | 14 | 54% | |
TNM stage | 0.029 | ||||||
I | 11 | 14% | 8 | 15% | 3 | 12% | |
II | 50 | 63% | 38 | 70% | 12 | 46% | |
III | 19 | 24% | 8 | 15% | 11 | 42% | |
Neoadjuvant chemotherapy regimen | 0.285 | ||||||
Anthracycline ± taxane | 16 | 20% | 8 | 15% | 8 | 31% | |
Anthracycline/taxane/platinum | 13 | 16% | 9 | 17% | 4 | 15% | |
Taxane/platinum | 49 | 61% | 36 | 67% | 13 | 50% | |
Taxane | 2 | 3% | 1 | 2% | 1 | 4% | |
Neoadjuvant immunotherapy | 0.644 | ||||||
No | 61 | 76% | 42 | 78% | 19 | 73% | |
Yes | 19 | 24% | 12 | 22% | 7 | 27% | |
Surgery type | 0.048 | ||||||
Lumpectomy | 24 | 30% | 29 | 37% | 4 | 15% | |
Mastectomy | 56 | 70% | 34 | 63% | 22 | 85% | |
Adjuvant radiotherapy | 0.924 | ||||||
Yes | 59 | 74% | 40 | 74% | 19 | 73% | |
No | 21 | 26% | 14 | 26% | 7 | 27% | |
Adjuvant chemotherapy | 0.877 | ||||||
Yes | 39 | 49% | 26 | 48% | 13 | 50% | |
No | 41 | 51% | 28 | 52% | 13 | 50% | |
